Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does USTEKINUMAB Cause Intentional product use issue? 1,788 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 1,788 reports of Intentional product use issue have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 2.1% of all adverse event reports for USTEKINUMAB.

1,788
Reports of Intentional product use issue with USTEKINUMAB
2.1%
of all USTEKINUMAB reports
895
Deaths
1,056
Hospitalizations

How Dangerous Is Intentional product use issue From USTEKINUMAB?

Of the 1,788 reports, 895 (50.1%) resulted in death, 1,056 (59.1%) required hospitalization, and 1,100 (61.5%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 1,788 reports have been filed with the FAERS database.

What Other Side Effects Does USTEKINUMAB Cause?

Drug ineffective (12,471) Off label use (10,990) Product dose omission issue (9,405) Fatigue (5,457) Product use issue (5,008) Psoriasis (4,955) Pain (4,872) Rash (4,736) Crohn's disease (4,662) Arthralgia (4,608)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which USTEKINUMAB Alternatives Have Lower Intentional product use issue Risk?

USTEKINUMAB vs USTEKINUMAB-STBA USTEKINUMAB vs VADADUSTAT USTEKINUMAB vs VALACYCLOVIR USTEKINUMAB vs VALBENAZINE USTEKINUMAB vs VALBENAZINE DITOSYLATE

Related Pages

USTEKINUMAB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue USTEKINUMAB Demographics